EW · Edwards Lifesciences Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 1, 2020; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $0.78 | the second quarter of 2026 | — |
|
|
|||
| Adjusted gross profit margin non-GAAP | 77.6% | the second quarter of 2026 | — |
|
|
|||
| Adjusted operating profit margin non-GAAP | 30% | the second quarter of 2026 | — |
|
|
|||
| Surgical sales | 284M | the second quarter | — |
|
|
|||
| TAVR sales | 1.26B | Q2 2026 | — |
|
|
|||
| TMTT sales non-GAAP | 195.9M | Q2 2026 | — |
|
|
|||
| Constant currency growth rate non-GAAP | 10.6% | 4Q 2025 | — |
| Constant currency growth rate - Europe non-GAAP | 11.9% | 4Q 2025 | — |
| Constant currency growth rate - Japan non-GAAP | 3.9% | 4Q 2025 | — |
| Constant currency growth rate - Outside of the United States non-GAAP | 11.7% | 4Q 2025 | — |
| Constant currency growth rate - Rest of World non-GAAP | 15.9% | 4Q 2025 | — |
| Constant currency growth rate - Structural Heart total non-GAAP | 11.6% | 4Q 2025 | — |
| Constant currency growth rate - Surgical Structural Heart non-GAAP | 2.2% | 4Q 2025 | — |
| Constant currency growth rate - TMTT non-GAAP | 44.1% | 4Q 2025 | — |
| Constant currency growth rate - United States non-GAAP | 11.6% | 4Q 2025 | — |
| Operating profit margin | 9.6% | Q4 FY2025 | — |
| Surgical constant currency sales growth non-GAAP | 2% | Q4 FY2025 | — |
| Surgical sales growth | 4% | Q4 FY2025 | — |
| TAVR sales growth | 12% | Q4 FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EW
this stock
Edwards Lifesciences Corp
|
$51.85B | +5.5% | +11.5% | 51.7 | 1.8% |
|
ABT
Abbott Laboratories
|
$198.74B | -10.9% | +5.7% | 32.0 | 1.2% |
|
SYK
Stryker Corp
|
$126.45B | -8.4% | +11.2% | 34.2 | 1.8% |
|
MDT
Medtronic plc
|
$117.57B | -6.3% | +8.4% | 24.6 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -51.1% | +12.5% | 19.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 1, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EW | +0.1% | +3.5% | +10.2% | +4.5% | +5.5% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -1.0% | -0.5% | -4.5% | +1.3% | -7.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.